Solexa given outperform rating by Leerink Swann

Solexa, Inc. was rated at outperform by Leerink Swann & Co. analyst John L. Sullivan. The analyst expects Solexa to launch the 1G Genome Analyzer, a next generation re-sequencing and expression analysis technology, in mid-2006. The company's patented approach to large-scale genetic analysis offers productivity benefits over legacy methods and targets an $800 million market. Shares of the Hayward, Calif., pharmaceutical company were up $0.64, or 7.23%, at $9.58 on volume of 168,544 shares versus the three-month running average of 114,760 shares. (Nasdaq: SLXA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.